Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Aryeh Sells 3,000 Shares of Stock

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Jason Aryeh sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $320.05, for a total value of $960,150.00. Following the transaction, the director owned 105,476 shares of the company’s stock, valued at $33,757,593.80. This trade represents a 2.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jason Aryeh also recently made the following trade(s):

  • On Wednesday, November 4th, Jason Aryeh sold 282 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $319.99, for a total value of $90,237.18.
  • On Monday, November 2nd, Jason Aryeh sold 700 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $320.43, for a total value of $224,301.00.
  • On Friday, October 30th, Jason Aryeh sold 1,411 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $320.24, for a total value of $451,858.64.

Ligand Pharmaceuticals Stock Performance

Ligand Pharmaceuticals stock opened at $316.27 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19. The stock has a fifty day moving average price of $301.33 and a two-hundred day moving average price of $257.45. Ligand Pharmaceuticals Incorporated has a 52-week low of $175.89 and a 52-week high of $326.63. The firm has a market capitalization of $6.33 billion, a P/E ratio of 141.19, a P/E/G ratio of 5.53 and a beta of 1.16.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.34. Ligand Pharmaceuticals had a return on equity of 5.22% and a net margin of 20.27%. The company had revenue of $78.75 million during the quarter, compared to analysts’ expectations of $77.00 million. During the same period last year, the business earned $3.09 earnings per share. The business’s revenue was down 31.8% on a year-over-year basis. As a group, analysts anticipate that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on LGND shares. Leerink Partners initiated coverage on shares of Ligand Pharmaceuticals in a report on Friday, August 14th. They set an “outperform” rating and a $330.00 price target for the company. Royal Bank Of Canada upped their price objective on shares of Ligand Pharmaceuticals from $345.00 to $357.00 and gave the stock an “outperform” rating in a research note on Friday, October 30th. Barclays raised their price objective on shares of Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday. Oppenheimer reiterated an “outperform” rating and issued a $326.00 target price (up from $285.00) on shares of Ligand Pharmaceuticals in a research note on Monday, August 3rd. Finally, Weiss Ratings downgraded Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a report on Monday, November 2nd. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $355.38.

Read Our Latest Research Report on LGND

Institutional Trading of Ligand Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in LGND. Ranger Investment Management L.P. bought a new position in shares of Ligand Pharmaceuticals in the second quarter valued at about $81,424,000. Bank of New York Mellon Corp bought a new stake in Ligand Pharmaceuticals during the 2nd quarter worth about $41,429,000. William Blair Investment Management LLC bought a new stake in Ligand Pharmaceuticals during the 3rd quarter worth about $37,264,000. Bessemer Group Inc. grew its holdings in Ligand Pharmaceuticals by 358.8% during the 1st quarter. Bessemer Group Inc. now owns 107,859 shares of the biotechnology company’s stock worth $21,535,000 after acquiring an additional 84,349 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Ligand Pharmaceuticals by 41.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 170,089 shares of the biotechnology company’s stock worth $53,131,000 after acquiring an additional 49,785 shares during the last quarter. 91.28% of the stock is currently owned by institutional investors and hedge funds.

Ligand Pharmaceuticals Company Profile

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

See Also

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.